|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Askoxylakis V, Thieke C, Pleger ST, Most
P, Tanner J, Lindel K, Katus HA, Debus J and Bischof M: Long-term
survival of cancer patients compared to heart failure and stroke: a
systematic review. BMC Cancer. 10:1052010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schaake EE, Kappers I, Codrington HE,
Valdés Olmos RA, Teertstra HJ, van Pel R, Burgers JA, van Tinteren
H and Klomp HM: Tumor response and toxicity of neoadjuvant
erlotinib in patients with early-stage non-small-cell lung cancer.
J Clin Oncol. 30:2731–2738. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, et al: Erlotinib in previously treated non-small-cell lung
cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fischer OM, Hart S, Gschwind A, Prenzel N
and Ullrich A: Oxidative and osmotic stress signaling in tumor
cells is mediated by ADAM proteases and heparin-binding epidermal
growth factor. Mol Cell Biol. 24:5172–5183. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mahimkar RM, Visaya O, Pollock AS and
Lovett DH: The disintegrin domain of ADAM9: a ligand for multiple
beta1 renal integrins. Biochem J. 385:461–468. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Singh B, Schneider M, Knyazev P and
Ullrich A: UV-induced EGFR signal transactivation is dependent on
proligand shedding by activated metalloproteases in skin cancer
cell lines. Int J Cancer. 124:531–539. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kenny PA and Bissell MJ: Targeting
TACE-dependent EGFR ligand shedding in breast cancer. J Clin
Invest. 117:337–345. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
McGowan PM, Ryan BM, Hill AD, McDermott E,
O’Higgins N and Duffy MJ: ADAM-17 expression in breast cancer
correlates with variables of tumor progression. Clin Cancer Res.
13:2335–2343. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ni SS, Zhang J, Zhao WL, Dong XC and Wang
JL: ADAM17 is overexpressed in non-small cell lung cancer and its
expression correlates with poor patient survival. Tumour Biol.
34:1813–1818. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang WY, Chen DH, Ning L and Wang LW:
siRNA mediated silencing of NIN1/RPN12 binding protein 1 homolog
inhibits proliferation and growth of breast cancer cells. Asian Pac
J Cancer Prev. 13:1823–1827. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Black RA: Tumor necrosis factor-alpha
converting enzyme. Int J Biochem Cell Biol. 34:1–5. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Primakoff P and Myles DG: The ADAM gene
family: surface proteins with adhesion and protease activity.
Trends Genet. 16:83–87. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Duffy MJ, McKiernan E, O’Donovan N and
McGowan P: Role of ADAMs in cancer formation and progression. Clin
Cancer Res. 15:1140–1144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Duffy MJ, McKiernan E, O’Donovan N and
McGowan P: The role of ADAMs in disease pathophysiology. Clin Chim
Acta. 403:31–36. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takamune Y, Ikebe T, Nagano O and
Shinohara M: Involvement of NF-kappaB-mediated maturation of
ADAM-17 in the invasion of oral squamous cell carcinoma. Biochem
Biophys Res Commun. 365:393–398. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng X, Jiang F, Katakowski M, Zhang ZG,
Lu QE and Chopp M: ADAM17 promotes breast cancer cell malignant
phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther.
8:1045–1105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ding X, Yang LY, Huang GW, Wang W and Lu
WQ: ADAM17 mRNA expression and pathological features of
hepatocellular carcinoma. World J Gastroenterol. 10:2735–2739.
2004.PubMed/NCBI
|
|
19
|
Gschwind A, Hart S, Fischer OM and Ullrich
A: TACE cleavage of proamphiregulin regulates GPCR-induced
proliferation and motility of cancer cells. EMBO J. 22:2411–2421.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hart S, Fischer OM and Ullrich A:
Cannabinoids induce cancer cell proliferation via tumor necrosis
factor α-converting enzyme (TACE/ADAM17)-mediated transactivation
of the epidermal growth factor receptor. Cancer Res. 64:1943–1950.
2004.PubMed/NCBI
|
|
21
|
Niculescu AB III, Chen X, Smeets M, Hengst
L, Prives C and Reed SI: Effects of p21(Cip1/Waf1) at both the G1/S
and the G2/M cell cycle transitions: pRb is a critical determinant
in blocking DNA replication and in preventing endoreduplication.
Mol Cell Biol. 18:629–643. 1998.PubMed/NCBI
|
|
22
|
Yu CC, Tsai LL, Wang ML, Yu CH, Lo WL,
Chang YC, Chiou GY, Chou MY and Chiou SH: miR145 targets the
SOX9/ADAM17 axis to inhibit tumor-initiating cells and
IL-6-mediated paracrine effects in head and neck cancer. Cancer
Res. 73:3425–3440. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mochizuki S and Okada Y: ADAMs in cancer
cell proliferation and progression. Cancer Sci. 98:621–628. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rocks N, Paulissen G, El Hour M, Quesada
F, Crahay C, Gueders M, Foidart JM, Noel A and Cataldo D: Emerging
roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie.
90:369–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
